UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa - Marketscreener.com
| UCBJF Stock | USD 174.00 0.00 0.00% |
Roughly 61% of UCB SA's investor base is looking to short. The analysis of overall sentiment of trading UCB SA pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with UCB SA's historical and current headlines, can help investors time the market. In addition, many technical investors use UCB SA stock news signals to limit their universe of possible portfolio assets.
UCB SA pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of UCB daily returns and investor perception about the current price of UCB SA as well as its diversification or hedging effects on your existing portfolios.
UCB |
UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa Marketscreener.com
Read at news.google.com
 |
UCB SA Fundamental Analysis
We analyze UCB SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UCB SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UCB SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
UCB SA is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
UCB SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with UCB SA pink sheet to make a market-neutral strategy. Peer analysis of UCB SA could also be used in its relative valuation, which is a method of valuing UCB SA by comparing valuation metrics with similar companies.
Peers
UCB SA Related Equities
| VRCA | Verrica Pharmaceuticals | 12.12 | ||||
| RCUS | Arcus Biosciences | 8.45 | ||||
| BOLT | Bolt Biotherapeutics | 5.00 | ||||
| VINC | Vincerx Pharma | 4.00 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| CVKD | Cadrenal Therapeutics, | 1.11 | ||||
| IBIO | Ibio | 0.78 | ||||
| OCGN | Ocugen | 1.09 | ||||
| IKNA | Ikena Oncology | 1.16 | ||||
| ADAG | Adagene | 2.20 | ||||
| HOTH | Hoth Therapeutics | 2.44 | ||||
| JAGX | Jaguar Animal | 2.91 | ||||
| SNTI | Senti Biosciences | 3.21 | ||||
| CARA | Cara Therapeutic | 3.33 | ||||
| FHTX | Foghorn Therapeutics | 4.81 | ||||
| FRES | Fresh2 | 6.14 | ||||
| KA | Kineta | 7.69 | ||||
| GOVX | GeoVax Labs | 10.30 |
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |